Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 463  
Year : 2020  |  Volume : 19  |  Issue : 1  |  Page : 65-68

Rapid progression of carcinoma en cuirasse breast dermal metastases on18F-fludeoxyglucose positron emission tomography–computed tomography

1 Department of Radiology, Yale New Haven Hospital, New Haven, CT, USA
2 Department of Pathology, Yale New Haven Hospital, New Haven, CT, USA

Correspondence Address:
Dr. Colin Raymond Young
Department of Radiology, Yale New Haven Hospital, 20 York Street, New Haven, CT 06510
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/wjnm.WJNM_37_19

Rights and Permissions

Cancer in the dermis of the breast has a poor prognosis. The breast dermis can become malignantly involved primarily in inflammatory breast cancer, through the direct extension of locally advanced breast cancer, or metastatically from an underlying breast mass or a distant primary malignancy (e.g., gastric adenocarcinoma). Breast dermal metastases have the shortest median survival among them. Breast dermal metastases are classified into eight clinicohistopathologic groups, one of which is carcinoma en cuirasse. We present a case of a 52-year-old female with a history of invasive ductal carcinoma, Stage IIIC (pT2N3a), treated with lumpectomy, axillary node dissection, and chemoradiation therapy that recurred as carcinoma en cuirasse breast dermal metastases. Through18F-fludeoxyglucose positron emission tomography–computed tomography (18F-FDG PET-CT) and clinical images, the case illustrates the rapid progression and devastating consequences of carcinoma en cuirasse breast dermal metastases over a 4-month period despite optimal therapy. Furthermore, the case emphasizes the sensitivity of18F-FDG PET-CT to detect pathology in the breast dermis. Finally, the case highlights the crucial role that nuclear medicine physicians play in helping clinical colleagues differentiate between the various breast dermal malignant manifestations and benign mastitis, a common confounder in postradiation patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded135    
    Comments [Add]    

Recommend this journal